comprehensive -WSS

comprehensive

author：explore 2025-09-06 02:12:54 - browse：11

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Why age limits for politicians are a terrible idea

WSS

Why drug prescriptions should include diagnoses

Why age limits for politicians are a terrible idea

Chan Zuckerberg Biohub Chicago to focus on inflammation

Chan Zuckerberg Biohub Chicago to focus on inflammation

Colonoscopy at 40? Study finds a possible benefit

3 questions for the future of Biden's cancer moonshot

hotspot

comprehensive

knowledge

Activists slam private health insurers over coverage restrictions

Colonoscopy at 40? Study finds a possible benefit

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

CDC concerned about possible undetected monkeypox spread in U.K.

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

With FDA staff opposed to Sarepta therapy, top official intervened

BioMarin wins approval for gene therapy to treat hemophilia A

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Moonlake's readout produced a cash windfall. Risks remain

A virus, fished out of a lake, may have saved a man’s life

knowledge

Sana to lay off nearly a third of staff, de

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Why drug prescriptions should include diagnoses

What to expect at HLTH 2023, the health care industry conference

Weight bias in eating disorder treatment complicated by new weight loss drugs

Death of patient in Alzheimer’s trial raises question of possible risks

explore

leisure time

explore

leisure time